Recurrent mRNA (BNT162b2) Covid-19 Vaccine-Associated Pericarditis in an Elderly Man with Multiple Comorbidities

Goenawan, Angel; Kussaga, Frank; Schwartz, Kenneth A.; D’Souza, Seema

doi:10.12691/ajmcr-9-12-12

Cited by 2 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All episodes of pericarditis were found after immunisation with BNT162b2. The pericarditis symptoms appeared after the second vaccine dose in three patients, 62,69 three after the first dose, 45,69 and one patient after both doses 68 . The median time from vaccination to onset of the first symptoms was 4 days (ranging from one to 11 days) (Tables 1 and ).…”

Section: Resultsmentioning

confidence: 97%

“…In addition, a previous history of pericarditis was found in three patients. 45,62,68 There were no confirmed COVID-19 infections prior to vaccination, with no patients testing positive for SARS-CoV-2 or any other viral infection. All episodes of pericarditis were found after immunisation with BNT162b2.…”

Section: Pericarditismentioning

confidence: 99%

“…[55][56][57][58][59][60][61][62][63][64][65][66][67] Overall, 227 patients were diagnosed as cases of myocarditis/myopericarditis from 61 studies, along with 7 patients with pericarditis. 45,62,68,69 The details on each case are presented in the supplementary material. Meanwhile, other rare cardiac manifestations were reported as four patients with Takotsubo cardiomyopathy, 56,61,69,70 three with myocardial infarction (MI), 61,66,71 one with myocardial infarction with non-obstructive coronary arteries (MINOCA), 61 and one with isolated tachycardia.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…The median age of the seven patients 45,62,68,69 who were diagnosed as isolated cases of pericarditis was 21 years (ranging from 21-to 80-year-old patients), with 71.4% being male. Almost half (42.8%) were from the United States, 28.6% from Israel and 28.6% from other countries.…”

Section: Pericarditismentioning

confidence: 99%

“…The pericarditis symptoms appeared after the second vaccine dose in three patients, 62,69 three after the first dose, 45,69 and one patient after both doses. 68 The median time from vaccination to onset of the first symptoms was 4 days (ranging from one to 11 days) (Tables 1 and S9). were elevated in 80% and 66.6% of cases, respectively (Table 2).…”

Section: Pericarditismentioning

confidence: 99%

See 4 more Smart Citations

Cardiac complications following mRNA COVID‐19 vaccines: A systematic review of case reports and case series

Fazlollahi

Zahmatyar

Noori

et al. 2021

Reviews in Medical Virology

View full text Add to dashboard Cite

There have been several local and systemic adverse events associated with mRNA COVID-19 vaccines. Pericarditis, myocarditis and myocardial infarction are examples of cardiac complications related to these vaccines. In this article, we conducted a systematic review of case reports and case series to identify the clinical profile, investigations, and management of reported cardiac complications post-mRNA COVID-19 vaccines. We systematically searched PubMed, Scopus, Web of Science, and Google Scholar, as well as the medRxiv preprint server, with terms including: 'SARS-CoV-2', 'COVID-19', 'messenger RNA vaccine*', 'mRNA-1273 vaccine', 'BNT162 vaccine', 'myocarditis', 'pericarditis', 'stroke' and 'Myocardial Ischemia' up to 25 September 2021. Studies were excluded if they were not case reports or case series, or reported cases from non-mRNA vaccines. Case reports and case series were included that investigated the potential cardiac complications associated with mRNA COVID-19 vaccines. The JBI checklist was used to assess quality and data synthesis was conducted using a qualitative methodology called narrative synthesis. Sixty-nine studies, including 43 case reports and 26 case series, were included. Myocarditis/myopericarditis and pericarditis were the most common adverse events among the 243 reported cardiac complications, post mRNA COVID-19 vaccination. Males with a median age of 21 years had the highest frequency of myocarditis. Almost three quarters (74.4%) of cases with myocarditis had received the BNT162b2 vaccine and 87.7% had received the second dose of the vaccine.Chest pain (96.1%) and fever (38.2%) were the most common presentations. CK-MB, troponin, and NT-proBNP were elevated in 100%, 99.5% and 78.3% of subjects, respectively. ST-segment abnormality was the most common electrocardiogram feature. Cardiac magnetic resonance imaging, which is the gold-standard approach for diagnosing myocarditis, was abnormal in all patients diagnosed with

show abstract

Section: Resultsmentioning

confidence: 97%

Section: Pericarditismentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Pericarditismentioning

confidence: 99%

Section: Pericarditismentioning

confidence: 99%

See 3 more Smart Citations

Cardiac complications following mRNA COVID‐19 vaccines: A systematic review of case reports and case series

Fazlollahi

Zahmatyar

Noori

et al. 2021

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

Myocarditis Following COVID-19 Vaccination: Cardiac Imaging Findings in 118 Studies

Keshavarz

Yazdanpanah

Emad³

et al. 2022

Tomography

View full text Add to dashboard Cite

We reviewed the reported imaging findings of myocarditis in the literature following COVID-19 vaccination on cardiac imaging by a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), and Google Scholar. In total, 532 cases of myocarditis after COVID-19 vaccination were reported (462, 86.8% men and 70, 13.2% women, age range 12 to 80) with the following distribution: Pfizer-BioNTech: 367 (69%), Moderna: 137 (25.8%), AstraZeneca: 12 (2.3%), Janssen/Johnson & Johnson: 6 (1.1%), COVAXIN: 1 (0.1%), and unknown mRNA vaccine: 9 (1.7%). The distribution of patients receiving vaccine dosage was investigated. On cardiac MR Imaging, late intravenous gadolinium enhancement (LGE) was observed mainly in the epicardial/subepicardial segments (90.8%, 318 of 350 enhancing segments), with the dominance of inferolateral segment and inferior walls. Pericardial effusion was reported in 13.1% of cases. The vast majority of patients (94%, 500 of 532) were discharged from the hospital except for 4 (0.7%) cases. Post-COVID-19 myocarditis was most commonly reported in symptomatic men after the second or third dose, with CMRI findings including LGE in 90.8% of inferior and inferolateral epicardial/subepicardial segments. Most cases were self-limited.

show abstract

Recurrent mRNA (BNT162b2) Covid-19 Vaccine-Associated Pericarditis in an Elderly Man with Multiple Comorbidities

Cited by 2 publications

References 0 publications

Cardiac complications following mRNA COVID‐19 vaccines: A systematic review of case reports and case series

Cardiac complications following mRNA COVID‐19 vaccines: A systematic review of case reports and case series

Myocarditis Following COVID-19 Vaccination: Cardiac Imaging Findings in 118 Studies

Contact Info

Product

Resources

About